Key facts
- This page summarizes Garry E. Menzel's Form 4 filing for Adaptimmune Therapeutics PLC (ADAP).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 10 Jul 2023, 17:01.
Garry E. Menzel - 10 Jul 2023 Form 4 Insider Report for Adaptimmune Therapeutics PLC (ADAP)
- Reporting relationship
- Director
- Issuer ticker
- ADAP
- Reported as of
- 10 Jul 2023
- Net transaction value
- -$43,447
- SEC form
- 4
- Accepted by SEC
- 10 Jul 2023, 17:01:03 UTC
- Prior SEC filing
- 05 Jul 2023
- Next SEC filing
- 07 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Garry E. Menzel**
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Garry E. Menzel filed Form 4 for Adaptimmune Therapeutics PLC (ADAP) on 10 Jul 2023.
Change
- Previous filing in this sequence was filed on 05 Jul 2023.
- Current net transaction value: -$43,447.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ADAP
transaction
American Depositary Shares representing Ordinary Shares
Sale
- Transaction value
- $43,447
- Shares
- -47,702
- Change %
- -39%
- Price
- $0.9108
- Shares after
- 75,056
- Date
- 10 Jul 2023
- Ownership
- Direct
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of 100% of an RSU-style share option covering ordinary shares of the Issuer granted on July 5, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.
Footnote F2
The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.9100 to $0.9211, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.
Footnote F3
The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 611,224 ADSs and share options covering an aggregate of 11,093,593 ordinary shares of the Issuer. Included in the 611,224 ADSs are 200,646 ADSs held by the Garry E. Menzel Revocable Trust of 2022 (the "Menzel Trust") and 200,647 ADSs held by the Mary E. Henshall Revocable Trust of 2022 (the "Henshall Trust"). The Reporting Person is the trustee of the Menzel Trust and the Reporting Person's spouse is the trustee of the Henshall Trust and, as such, the Reporting Person may be deemed to beneficially own these securities. The Reporting Person and members of his immediate family are the sole beneficiaries of the Menzel Trust and the Henshall Trust.